Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Abeona licenses UNC-Chapel Hill's AIM AAV gene therapy for Batten disease

Executive Summary

Abeona Therapeutics Inc. licensed exclusive worldwide rights to the University of North Carolina at Chapel Hill's AIM adeno-associated virus (AAV) gene therapy vector platform, which targets the central nervous system, and an associated gene therapy ABO202 (AAV-CLN1) for infantile neuronal ceroid lipofuscinosis, also known as juvenile Batten disease (JBD).
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies